Allergic rhinitis (AR) is a significant health issue that affects quality of life (QoL). The ARIA classification system, based on symptom duration and severity, distinguishes between intermittent and persistent AR (PER). PER is defined as symptoms lasting more than 4 days per week and for more than 4 consecutive weeks. Levocetirizine, a potent H1-receptor antagonist, is the best studied treatment for PER. It has shown significant improvement in nasal symptoms, including nasal congestion, and enhanced QoL in clinical trials. The XPERT trial demonstrated that levocetirizine (5 mg/day) significantly improved symptoms as early as the first week and maintained effectiveness over 6 months. It was well tolerated and provided substantial cost savings for society and employers. Levocetirizine is effective in both seasonal and perennial AR and is the first tested standard treatment for PER using the ARIA classification. It offers prompt relief of symptoms, improves QoL, and provides economic benefits. Other treatments include allergen avoidance, immunotherapy, and nasal steroids, but levocetirizine is currently the best studied option for PER. It is effective in reducing nasal congestion, improving airflow, and reducing comorbidities like asthma. Overall, levocetirizine is a key treatment for PER due to its efficacy, safety, and cost-effectiveness.Allergic rhinitis (AR) is a significant health issue that affects quality of life (QoL). The ARIA classification system, based on symptom duration and severity, distinguishes between intermittent and persistent AR (PER). PER is defined as symptoms lasting more than 4 days per week and for more than 4 consecutive weeks. Levocetirizine, a potent H1-receptor antagonist, is the best studied treatment for PER. It has shown significant improvement in nasal symptoms, including nasal congestion, and enhanced QoL in clinical trials. The XPERT trial demonstrated that levocetirizine (5 mg/day) significantly improved symptoms as early as the first week and maintained effectiveness over 6 months. It was well tolerated and provided substantial cost savings for society and employers. Levocetirizine is effective in both seasonal and perennial AR and is the first tested standard treatment for PER using the ARIA classification. It offers prompt relief of symptoms, improves QoL, and provides economic benefits. Other treatments include allergen avoidance, immunotherapy, and nasal steroids, but levocetirizine is currently the best studied option for PER. It is effective in reducing nasal congestion, improving airflow, and reducing comorbidities like asthma. Overall, levocetirizine is a key treatment for PER due to its efficacy, safety, and cost-effectiveness.